Literature DB >> 30115651

A Systemic Inflammatory Signature Reflecting Cross Talk Between Innate and Adaptive Immunity Is Associated With Incident Polyneuropathy: KORA F4/FF4 Study.

Christian Herder1,2,3, Julia M Kannenberg4,2, Maren Carstensen-Kirberg4,2, Alexander Strom4,2, Gidon J Bönhof4, Wolfgang Rathmann2,5, Cornelia Huth2,6, Wolfgang Koenig7,8,9, Margit Heier6, Jan Krumsiek2,10,11, Annette Peters2,6, Christa Meisinger2,6,12, Michael Roden4,2,3, Barbara Thorand2,6, Dan Ziegler4,2,3.   

Abstract

Prospective analyses of biomarkers of inflammation and distal sensorimotor polyneuropathy (DSPN) are scarce and limited to innate immunity. We therefore aimed to assess associations between biomarkers reflecting multiple aspects of immune activation and DSPN. The study was based on 127 case subjects with incident DSPN and 386 noncase subjects from the population-based Cooperative Health Research in the Region of Augsburg (KORA) F4/FF4 cohort (follow-up 6.5 years). Proximity extension assay technology was used to measure serum levels of biomarkers of inflammation. Of 71 biomarkers assessed, 26 were associated with incident DSPN. After adjustment for multiple testing, higher levels of six biomarkers remained related to incident DSPN. Three of these proteins (MCP-3/CCL7, MIG/CXCL9, IP-10/CXCL10) were chemokines, and the other three (DNER, CD40, TNFRSF9) were soluble forms of transmembrane receptors. The chemokines had neurotoxic effects on neuroblastoma cells in vitro. Addition of all six biomarkers improved the C statistic of a clinical risk model from 0.748 to 0.783 (P = 0.011). Pathway analyses indicated that multiple cell types from innate and adaptive immunity are involved in the development of DSPN. We thus identified novel associations between biomarkers of inflammation and incident DSPN pointing to a complex cross talk between innate and adaptive immunity in the pathogenesis of the disease.
© 2018 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30115651     DOI: 10.2337/db18-0060

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  12 in total

Review 1.  Inflammation in the Pathophysiology and Therapy of Cardiometabolic Disease.

Authors:  Marc Y Donath; Daniel T Meier; Marianne Böni-Schnetzler
Journal:  Endocr Rev       Date:  2019-08-01       Impact factor: 19.871

Review 2.  Subclinical inflammation and depressive symptoms in patients with type 1 and type 2 diabetes.

Authors:  Christian Herder; Norbert Hermanns
Journal:  Semin Immunopathol       Date:  2019-02-18       Impact factor: 9.623

3.  Increased Release of Proinflammatory Proteins in Primary Human Adipocytes and Activation of the Inflammatory NFĸB, p38, and ERK Pathways upon Omentin Treatment.

Authors:  Corinna Niersmann; Karin Röhrig; Matthias Blüher; Michael Roden; Christian Herder; Maren Carstensen-Kirberg
Journal:  Obes Facts       Date:  2020-04-06       Impact factor: 3.942

Review 4.  Inflammation in obesity, diabetes, and related disorders.

Authors:  Theresa V Rohm; Daniel T Meier; Jerrold M Olefsky; Marc Y Donath
Journal:  Immunity       Date:  2022-01-11       Impact factor: 31.745

5.  A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection.

Authors:  Michael P Dubé; Ellen S Chan; Jordan E Lake; Brett Williams; Jennifer Kinslow; Alan Landay; Robert W Coombs; Michelle Floris-Moore; Heather J Ribaudo; Kevin E Yarasheski
Journal:  Clin Infect Dis       Date:  2019-09-13       Impact factor: 20.999

6.  Deficits in systemic biomarkers of neuroinflammation and growth factors promoting nerve regeneration in patients with type 2 diabetes and polyneuropathy.

Authors:  Dan Ziegler; Alexander Strom; Gidon J Bönhof; Julia M Kannenberg; Margit Heier; Wolfgang Rathmann; Annette Peters; Christina Meisinger; Michael Roden; Barbara Thorand; Christian Herder
Journal:  BMJ Open Diabetes Res Care       Date:  2019-11-27

7.  Plasma Proteome Profiling to detect and avoid sample-related biases in biomarker studies.

Authors:  Philipp E Geyer; Eugenia Voytik; Peter V Treit; Sophia Doll; Alisa Kleinhempel; Lili Niu; Johannes B Müller; Marie-Luise Buchholtz; Jakob M Bader; Daniel Teupser; Lesca M Holdt; Matthias Mann
Journal:  EMBO Mol Med       Date:  2019-09-30       Impact factor: 12.137

8.  Associations of cells from both innate and adaptive immunity with lower nerve conduction velocity: the Maastricht Study.

Authors:  Haifa Maalmi; Kristiaan Wouters; Christian Herder; Nicolaas C Schaper; Hans H C M Savelberg; Jeroen H P M van der Velde; Jos P H Reulen; Werner Mess; Casper G Schalkwijk; Coen D A Stehouwer; Michael Roden; Dan Ziegler
Journal:  BMJ Open Diabetes Res Care       Date:  2021-01

Review 9.  Targeting innate immune mediators in type 1 and type 2 diabetes.

Authors:  Marc Y Donath; Charles A Dinarello; Thomas Mandrup-Poulsen
Journal:  Nat Rev Immunol       Date:  2019-09-09       Impact factor: 53.106

10.  Specific gene expression in type 1 diabetic patients with and without cardiac autonomic neuropathy.

Authors:  Joanna Gastol; Anna Polus; Maria Biela; Urszula Razny; Lukasz Pawlinski; Bogdan Solnica; Beata Kiec-Wilk
Journal:  Sci Rep       Date:  2020-03-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.